IPP Bureau
AstraZeneca receives CDSCO approval to launch eculizumab in India
By IPP Bureau - January 17, 2025
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
Bajaj Healthcare receives exclusive rights for manufacturing, distribution & sales of finished formulation of Magnesium L Threonate
By IPP Bureau - January 17, 2025
The brand Magtein by Threotech has a sales value of approximately US $438 million
FDA issues five observations to Jubilant Pharmova’s Salisbury facility in USA
By IPP Bureau - January 17, 2025
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
Sun Pharma to acquire 100% stake in Antibe Therapeutics
By IPP Bureau - January 17, 2025
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
AbbVie partners with Simcere Zaiming to develop Novel Trispecific Antibody Candidate in Multiple Myeloma
By IPP Bureau - January 17, 2025
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Alleima completes the acquisition of medical components firm Endox
By IPP Bureau - January 16, 2025
In 2023, Endox had revenues of approximately SEK 65 million
Dr. Kathiresan Rajasekar appointed President – International Business, Gufic Biosciences
By IPP Bureau - January 16, 2025
With over 28 years of experience in the pharmaceutical industry, he is a seasoned Techno? Commercial professional and accomplished top management leader
Alembic announces USFDA final approval for Brexpiprazole Tablets
By IPP Bureau - January 16, 2025
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Briefs: Morepen Laboratories, Glenmark Life Sciences, Gland Pharma and Shalby
By IPP Bureau - January 16, 2025
Morepen Laboratories approves hiving off of medical devices business
USFDA will no longer allow for use of FD&C Red No. 3 in food and ingested drugs
By IPP Bureau - January 16, 2025
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
atulya launches winter essential kit for hair and skin care
By IPP Bureau - January 16, 2025
atulya keratin & wheat protein shampoo has force of natural ingredients like extract of wheat, fenugreek, reetha & almond oil
DBT hosts webinar on Biomanufacturing for Climate Resilient Agriculture
By IPP Bureau - January 15, 2025
Need for inter-sectoral collaboration, enhanced research, and innovative practices to address growing burden of NCDs: Health Secretary Srivastava
By IPP Bureau - January 15, 2025
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
Bayer’s pharma growth strategy progressing well as pipeline advances
By IPP Bureau - January 15, 2025
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Odisha to implement AB PM-JAY scheme
By IPP Bureau - January 14, 2025
The scheme is fully digitized and covers approximately 45% of India's population
